This study examines how well two combinations of medicines work for a specific type of lung cancer, called EGFR-mutated non-small cell lung cancer. The medicines are amivantamab and lazertinib, or amivantamab with chemotherapy. Amivantamab is an antibody, which is a protein that can help fight cancer. Lazertinib is a drug that blocks signals cancer uses to grow. Chemotherapy uses special medicines to kill cancer cells.

For this study, you need to have a confirmed case of advanced or spreading lung cancer that cannot be cured with surgery. You should have a certain type of mutation in your cancer cells. You should not have had major surgery or uncontrolled pain recently.

• **Study Length & Visits:** Discuss with your doctor for specific details.
• **Treatment:** You may receive either combination of medicines.
• **Risks:** Prior surgeries, pain, or other treatments might affect eligibility.